7 completed, 3 unknown, 2 recruiting, 1 withdrawn. 13 Phase 2, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 7, Unknown 3, Recruiting 2, Withdrawn 1 |
| Phase 3 | 6 | Completed 2, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow Dilatation, Pathologic: new trials by email Literature Review of Dilatation, Pathologic trials Research Report on Dilatation, Pathologic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement Ketorolac, oral ibuprofen, Placebo - Pain Management, Abortion | Phase 2 | Recruiting | Rush University Medical Center | 76 | 2026-06-29 | 2026-07-06 |
| Anticholinergics for Cervical Edema in Labor Treatment with Diphenhydramine, Usual Care - Labor Dystocia | Phase 2 / Phase 3 | Recruiting | The University of Texas Health Science Center, Houston | 200 | 2025-03-25 | 2026-05-06 |
| Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation Tranexamic acid, Placebo - Abortion, Dilation and Evacuation | Phase 2 | Completed | University of Hawaii | 50 | 2022-02-15 | 2026-11-02 |
| Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) - Mydriasis, Dilation | Phase 2 | Completed | Opus Genetics, Inc | 32 | 2019-08-13 | 2026-10-30 |
| UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia UV-X Light, Riboflavin - Keratoconus, Ectasia | Phase 2 | Unknown | Mercy Center for Corrective Eye Surgery | 250 | 2011-03-01 | 2011-03-29 |
| Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia Riboflavin, UVX light - Keratoconus, Post-Refractive Ectasia | Phase 2 | Completed | Price Vision Group | 510 | 2010-05-01 | 2018-06-06 |
| Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs Riboflavin - Keratoconus, Ectasia | Phase 2 / Phase 3 | Unknown | Yaron S. Rabinowitz M.D. | 600 | 2009-01-21 | 2018-10-02 |
| Treatment of Keratoconus Using Collagen Cross-Linking Riboflavin-5-phosphate, Sham cross-linking - Keratoconus | Phase 2 / Phase 3 | Unknown | University at Buffalo | 150 | 2008-09-01 | 2009-02-11 |
| Corneal Crosslinking in Keratoconus and Corneal Ectasia Riboflavin, Placebo - Progressive Keratoconus, Corneal Ectasia | Phase 2 / Phase 3 | Withdrawn | Ohio State University | 2008-04-01 | 2017-04-20 | |
| Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia Corneal collagen, Sham comparator - Progressive Keratoconus, Corneal Ectasia | Phase 2 / Phase 3 | Completed | Emory University | 160 | 2007-12-01 | 2010-09-02 |
| A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. AQUAVAN® (fospropofol disodium) Injection - Procedural Sedation | Phase 2 / Phase 3 | Completed | Eisai Inc. | 123 | 2006-05-01 | 2012-06-20 |
| Laser Treatment Of Vascular Lesions On Vocal Cords Pulse Dye laser (PDL), CO2 laser or other traditional surgeries - Ectasia | Phase 2 | Completed | Boston University | 7 | 2005-03-01 | 2011-03-31 |
| Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia octreotide - Hereditary Hemorrhagic Telangiectasia, Ectasia | Phase 2 | Completed | National Center for Research Resources (NCRR) | 8 | 1995-01-01 | 2005-06-24 |
Keratoconus (6) · Corneal Diseases (4) · Agnosia (1) · Arteriovenous Fistula (1) · Bunion (1) · Dystocia (1) · Eye Diseases (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemorrhage (1) · Mydriasis (1) · Rare Diseases (1) · Telangiectasia, Hereditary Hemorrhagic (1)
Pathological Conditions, Anatomical (13) · Pathological Conditions, Signs and Symptoms (13) · Eye Diseases (6) · Cardiovascular Abnormalities (2) · Cardiovascular Diseases (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Corneal Diseases (2) · Pathologic Processes (2) · Vascular Diseases (2) · Vascular Malformations (2) · Arteriovenous Malformations (1) · Disease Attributes (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fistula (1)
Riboflavin (4) · Corneal Cross-Linking (1) · Diphenhydramine (1) · Fibrillins (1) · Flavin Mononucleotide (1) · Ibuprofen (1) · Injections (1) · Ketorolac (1) · Lasers, Gas (1) · Lubricant Eye Drops (1) · Octreotide (1) · Sodium Chloride (1) · Therapeutics (1) · Tranexamic Acid (1) · fospropofol (1)
Boston University (1) · Eisai Inc. (1) · Emory University (1) · Mercy Center for Corrective Eye Surgery (1) · National Center for Research Resources (NCRR) (1) · Ohio State University (1) · Opus Genetics, Inc (1) · Price Vision Group (1) · Rush University Medical Center (1) · The University of Texas Health Science Center, Houston (1) · University at Buffalo (1) · University of Hawaii (1) · Yaron S. Rabinowitz M.D. (1)
United States (11)
Ezra Maguen, M.D. (1) · Francis W Price, MD (1) · James B Jones, MD, PharmD (1) · James J Reidy, M.D. (1) · James Salz, M.D. (1) · Joshua R. Korzenik (1) · Kathryn Crofton, MD (1) · Marit Pearlman Shapiro (1) · R. Doyle Stulting, MD, PhD (1) · Richard Keates, MD (1) · Robert L Epstein, MD (1) · Ronald Gaster, MD (1) · Sadia MA Haider, MD, MPH (1) · Samantha Antonioli, MD (1) · Yaron S Rabinowitz, M.D. (1)
PMID 16765803, PMID 16952090, PMID 12719068, PMID 16565005, PMID 16900027, PMID 17457183, PMID 17457184, PMID 17531694, PMID 17720054, PMID 18471635, PMID 18811118, PMID 20138607, PMID 20164744, PMID 25365551, PMID 29203068, PMID 33633016
R21DC006853 (1)